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Background: There is a concern that some, especially older people, are not referred and could benefit from
transplantation.
Methods: We retrospectively examined consecutive incident end stage renal disease (ESRD) patients at our center
from January 2006 to December 2009. At ESRD start, patients were classified into those with or without
contraindications using Canadian eligibility criteria. Based on referral for transplantation, patients were grouped as
CANDIDATE (no contraindication and referred), NEITHER (no contraindication and not referred) and
CONTRAINDICATION. The Charlson Comorbidity Index (CCI) was used to assess comorbidity burden.
Results: Of the 437 patients, 133 (30.4%) were CANDIDATE (mean age 50 and CCI 3.0), 59 (13.5%) were NEITHER
(age 76 and CCI 4.4), and 245 (56.1%) were CONTRAINDICATION (age 65 and CCI 5.5). Age was the best
discriminator between NEITHER and CANDIDATES (c-statistic 0.96, P <0.0001) with CCI being less discriminative
(0.692, P <0.001). CANDIDATES had excellent survival whereas those patients designated NEITHER and
CONTRAINDICATION had high mortality rates. NEITHER patients died or developed a contraindication at very high
rates. By 1.5 years 50% of the NEITHER patients were no longer eligible for a transplant.
Conclusions: There exists a relatively small population of incident patients not referred who have no
contraindications. These are older patients with significant comorbidity who have a small window of opportunity
for kidney transplantation.
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One of the most important tasks of a nephrologist is to
evaluate and refer patients with End Stage Renal Disease
(ESRD) for a kidney transplant. Kidney transplantation
provides a better quality of life, on average a longer life
and at a lower cost when compared to standard dialysis
[1]. Some have argued that many older patients are not
being transplanted because of ‘ageism’ [2,3]. In a small
prospective study we found that nearly 25% of incident
ESRD patients had no contraindications to transplant-
ation using published Canadian consensus recommenda-
tions and were not referred. The single most important
discriminating factor was age [4]. In those without con-
traindications to kidney transplantation, patients referred* Correspondence: bryce.kiberd@dal.ca
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reproduction in any medium, provided the orwere on average 50 years old whereas those not referred
were on average 75 years old.
Details are lacking on the subsequent outcomes of this
non-referred cohort that has no contraindication to
transplantation. One of the recommendations of the
Canadian consensus report on eligibility for transplant-
ation is that patients should have a reasonable probabil-
ity of surviving beyond the anticipated wait times for a
transplant [5]. In this study we sought to further evalu-
ate referral, listing and subsequent outcomes in a larger
cohort of patients starting ESRD therapy. Our hypoth-
esis is that there will be a subset of patients not referred
who would survive the wait list period free of contrain-
dications if no preemptive kidney was available. Identify-
ing this cohort would be important.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Patient flow.
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The cohort consisted of all consecutive adults (over 18
years of age) initiating ESRD therapy (preemptive trans-
plant, peritoneal or hemodialysis) at this single center
from 1 January 2006 to 31 December 2009. In addition,
patients with a failed transplant were also included since
these would normally be considered eligible for a
retransplant. Patients were from mainland Nova Scotia
(excluding Cape Breton) but the cohort did not include
patients from Yarmouth. There was an overlap with 33
patients from our previous study [4]. The inclusion
period of January 2006 was chosen as the start date as
this was when electronic health records became avail-
able. Follow-up ended 21 March 2011. Permission for
the study was obtained from Capital Heath Research
Ethics Board. Data Collection: Information on patient
age, gender, height, weight, comorbidities, and laboratory
(hemoglobin, albumin and creatinine) data at the time of
ESRD therapy was extracted from the hospital records.
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the modification of diet in renal disease
(MDRD) formula. The Charlson Comorbidity Index
(CCI) was used to quantify comorbidity burden [6]. The
CCI is calculated from the presence of comorbid condi-
tions (congestive heart failure, dementia, cancer, cerebral
vascular disease, severe renal disease etcetera), with each
condition being given a weight. The index did not in-
clude age. The transplant database was reviewed for evi-
dence of kidney transplantation referral. Candidacy on
those referred was determined by the Program’s trans-
plant wait list committee. For patients not referred, deci-
sions about candidacy were made by a consensus of the
authors (BK, RP, MA) after independent review of each
patient’s electronic records. A decision was made about
candidacy at the start of ESRD therapy. For patients
without a permanent contraindication a further evalu-
ation was made to determine if and when a permanent
contraindication occurred after the start of dialysis. As
per our previous paper, contraindications were based on
the Canadian Society of Transplantation’s consensus
document [5]. Critical contraindications included active
angina, acute coronary syndrome, myocardial infarction
or stroke within six months, active renal disease (that is,
vasculitis on treatment) that could recur in the trans-
plant, severe chronic obstructive lung disease, active per-
ipheral vascular disease, active infection, metastatic
cancer or cancer treated within the recommended wait
time. Obesity with a body mass index (BMI) greater than
40 kg/m2 was also considered a contraindication at our
center. Patients (n = 6) who refused the transplant op-
tion were classified under contraindication.
Statistical Analysis: Data were presented as means
(standard deviation) and by percentages. Differences be-
tween groups were tested by parametric and non-parametric tests where appropriate. Patients were cate-
gorized as transplant Candidate (referred and no contra-
indication), Contraindication, and Neither (not referred
and no contraindications). Receiver operating curves
were used to examine concordance between continuous
variables and Candidate versus Neither. Multivariable
binary logistic analysis was used to examine associations
between Candidate and Neither and baseline covariates.
Variables included in the analysis were age, gender, dia-
betes status, CCI (index score and individual comorbid-
ities), laboratory data (albumin, eGFR, hemoglobin), and
type of renal disease. A stepwise backward conditional
analysis was performed to identify significant predictors.
Patient survival was examined using the Kaplan-Meier
method. Log rank was used to detect differences be-
tween groups. Survival was censored at last follow-up
and at time of transplantation. A Cox hazard model was
used to examine variables associated with time to death
or time to development of a contraindication in the Nei-
ther group. Variables included in the analysis were age,
gender, diabetes mellitus status, CCI, laboratory data,
and type of renal disease. Individual comorbidities were
also examined. A stepwise backward conditional analysis
was performed to identify significant predictors. Statis-
tical analysis was performed using SPSS (11.1) software
(SPSS Inc. Chicago, IL).
Results
Of the 437 patients, 31 were those with failed trans-
plants returning to dialysis, 35 received preemptive
transplants and the remaining started hemodialysis or
peritoneal dialysis. The majority were Caucasian and
3.8% (n = 17) were Black. The mean follow-up time was
2.1 years (median was 1.9 years). Few (n = 2) were lost
to follow-up. In all, 205 (47%) were referred for trans-
plantation, 147 (33.6%) were eventually listed, 101
(23.1%) have been transplanted, 160 (36.6%) have died,
and initially 245 (56.1%) had contraindications to
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Figure 2 shows the breakdown of referral, wait list,
transplantation, and initial contraindication by age cat-
egories. Fewer older patients were referred and listed.
Of those patients age 70 to 79 years, 60% had an ini-
tial contraindication, 9.9% (10/111) were referred and
6.3% (7/111) were listed. None of those age 80 plus
years were referred and 72% of these had initial con-
traindications. Of the 245 patients who had an initial
contraindication, 72 were referred and 28 were subse-
quently activated. Those that were eventually referred
were between the ages of 25 and 68 years. No patient
more than 70 years old with an initial contraindication
was later referred, however only three of these older
subjects had a reversible contraindication before death.
Based on the initial evaluation at ESRD or return to
dialysis in the failed transplants, 133 (30.4%) patients
were referred, had no contraindications and were classi-
fied as Candidates. There were 59 (13.5%) patients with-
out contraindications who were not referred and were
categorized as Neither. The remaining 245 (56.1%) had a
Contraindication. Table 1 shows the demographics of
these cohorts. The Neither cohort was significantly older
than both the other groups and had significantly more
comorbidity than the Candidate group as judged by the
CCI.
Among the patients without a contraindication, age
was a very significant discriminating variable (Figure 3)
differentiating Candidates from Neither patients (c-stat-
istic 0.96, P <0.001). Other significant variables were
CCI (c = 0.692, P <0.001) and albumin (c = 0.659,
P = 0.002). In a multivariable logistic regression model
only age (Odds Ratio (OR) 1.4 per year, 95% CI 1.2, 1.6,
P <0.001) and CCI (OR 1.5 per unit, 95% CI 1.1, 2.0,
P = 0.013) were significant variables that distinguished
Candidates from Neither. Figure 4 shows patient survival
for each of the three cohorts. Neither and Contraindica-
tion patients had much higher mortality rates thanFigure 2 Patient disposition stratified by age.Candidates (P <0.001). Although mortality was higher
overall in the Contraindication group compared to the
Neither group, the survival curves were essentially paral-
lel after the first three to six months. To emphasize, pa-
tient survival was censored at time of transplant and
patients with a preemptive transplant were excluded
from the survival analysis. Excluding patients with a
failed transplant returning to dialysis did not change the
findings (data not shown).
In the subset of Neither patients, all were more than
60 years old. Figure 5 shows time to death and time to
death or to contraindication Median time to the devel-
opment of a contraindication or death was only 1.45
years. Reasons for later contraindication were vascular
([7], peripheral, cerebral or coronary artery disease), can-
cer [6], dementia [4], pulmonary disease [5] and other
[6]. In an additional nine subjects, death occurred before
any overt complication, leaving only 14 patients who
survived the follow-up period without contraindication.
In a multivariable Cox analysis only the presence of is-
chemic heart disease (OR 3.1, 95% CI 1.3, 7.3, P = 0.011)
was a significant predictor of developing a contraindica-
tion. There was a trend for peripheral vascular disease
(OR 2.1, 95% CI 0.92, 4.8, P = 0.077) to be associated.
Age, gender, diabetes status, CCI, other comorbidities,
laboratory data and type of renal disease were not
predictors.
Discussion
This study shows that there exists a small subset (<15%)
of incident dialysis patients who should be eligible for
and might benefit from kidney transplantation. This co-
hort is older with significant comorbidity and may be
shrinking in comparison to the 23% in our report from
five years earlier [4]. The unique finding of this study is
that this cohort not only has a mortality rate that is
similar to patients with transplant contraindications but
there is also a very good chance that these patients will
develop a contraindication within several years. Other
than vascular disease, there is little to predict who would
have survived or remain contraindication-free long
enough to receive a kidney transplant.
In comparison, our earlier study was prospective
whereas this one was retrospective [4]. Although there
was a small overlap, all 33 patients were classified the
same after a look back. In the current study slightly
more were referred (46.6% versus 41.6%), more had ini-
tial contraindications (56.1% versus 42.5%) and there
were fewer categorized as neither (13.5% versus 23%). It
is not clear whether these are significant trends. Surpris-
ingly, the mean ages of the three cohorts were almost
exactly the same between the two studies (Candidates 50
versus 50, Contraindications 65 versus 65, and Neither
75 versus 76).
Table 1 Baseline patient demographics by cohort
All Candidates Neither Contraindication Probability
N = 437 N = 133 N = 59 N = 245
Age (years) 62 ± 16 50 ± 14 76 ± 7 65 ± 14 <0.001
Gender male 249 (57%) 72 (54%) 30 (50.4%) 147 (60%) 0.325
ESRD
DM 121 (28%) 28 (21%) 15 (25%) 78 (32%) 0.311
PCKD 41 (9.3%) 28 (21%) 2 (3.4%) 11 (4.5%) <0.001
GN 56 (12.8%) 30 (23%) 4 (6.8%) 22 (9%) 0.001
BMI kg/m2 n = 368 29.2 ±7.8 28.0 ± 5.9 28.2 ± 5.8 30.1 ± 8.9 0.037
eGFR
ml/min/1.73 m2 8.8 ± 3.8 8.4 ± 3.8 9.2 ± 4.2 9.0 ± 3.7 0.368
Albumin g/L 32 ± 7 35 ± 6 32 ± 5 30 ± 6 <0.001
Hemoglobin g/L 100 ± 15 105 ± 17 103 ± 15 97 ± 18 <0.001
CCI 4.6 ± 2.7 3.0 ± 2.0 4.4 ± 2.3 5.5 ± 2.7 <0.001
BMI, body mass index; CCI, Charlson Comorbidity Index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; GN,
glomerulonephritis; PCKD, polycystic kidney disease.
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those patients age 70 to 79 years were referred. None of
the incident Candidates were older than 70 years of age
in the previous study although the program had older
prevalent patients on the wait list in 2006 [4]. Most, but
not all, studies have shown that older wait-listed patients
have better outcomes with deceased and live donor kid-
ney transplants than they have if remaining on dialysis
[8-11]. Studies have also projected that younger recipi-
ents would do better to wait for a standard criteria
donor organ than to receive an ECD (extended criteria
donor) organ if the wait time is not excessive, and older
patients would do better to accept an ECD organ quickly
rather than run the risk of dying while waiting for a
standard criteria organ [12]. Our center allocates ECD
donor kidneys preferentially to the older wait list candi-
dates. Given the increasing numbers of older donors,
this is an advantage to our older recipients and may haveFigure 3 Receiver operating curve for age and Charlson
Comorbidity Index in Candidates versus Neither patients.increased our willingness to place older candidates on
the list.
In regard to classifying more patients with contraindi-
cations, this cohort came from a more restricted catch-
ment area, was retrospective, and we had the benefit of
comprehensive electronic health records. This may have
helped document the presence or absence of contraindi-
cations. The overall CCI (5.5 versus 5.5) in the Contra-
indication subjects was the same between this and our
previous study [4]. Obesity as a sole reason for denying
access was observed in only four patients. Patient refusal
was observed in seven patients, of which only three were
over age 65. One older woman (age 68 years) nearly
completed the work-up pre-dialysis and then refused to
be listed.Figure 4 Patient survival based on initial classification.
Figure 5 Patient survival and time to Contraindication in the
Neither cohort.
AlBugami et al. Transplantation Research 2012, 1:22 Page 5 of 6
http://www.transplantationresearch.com/content/1/1/22Although the percentage of patients not referred with-
out contraindications is relatively small, it is a substan-
tial proportion (26.5%) of the older people (age 65 and
older). Mortality and rates of complications that would
result in removal from the wait list are very high. Since
transplant wait lists are growing and wait times exceed
three years in many centers, only about 3.5% (n = 14) of
patients were in retrospect disadvantaged by not having
undergone referral. In a recent analysis of US waitlisted
patients, almost half of those older than age 60 are likely
to die before being transplanted [13]. Annual mortality
rates after the second year of waiting increase to more
than 25 deaths per 100 patient years in wait-listed candi-
dates older than age 70 [9] There will be additional
patients who will have been taken off the list or put on
hold. Therefore our Neither (no contraindications and
not referred) cohort is likely to have even lower rates of
transplantation given competing risks of death and
illness compared to the current older wait-listed
population.
The study identifies two other subsets of patients who
have been disadvantaged. There were six patients with
initial contraindications that reversed at a later date and
who still have not been referred. All were older than 59
years of age. There were 14 additional patients who had
no contraindications but were referred and were never
listed. Of these, eight were older than 65 years of age.
Reasons for not listing were varied (failure to complete
work-up, later refused, death, later contraindication and
lost to follow). Of these 20 patients in total, only four
have died.
One of the limitations of this study is that not every-
one underwent a formal transplant evaluation. This was
a retrospective chart review and decisions were made by
three individuals, two of whom were part of the earlier
study. It is possible the Neither group could be smaller ifall underwent a thorough transplant evaluation. On the
other hand the group could be larger as other centers
might disagree with our decisions. We point out that the
mortality in the group with initial contraindications by
our interpretation of the Canadian guidelines was very
high with a median survival of 2.9 years, and for those
with persistent contraindications and who were 60 years
or older median survival was only 2.3 years (data not
shown). More aggressive listing centers might have seen
greater mortality in their Candidates (death on the list)
with greater delisting from illness and a smaller Neither
group. Less aggressive listing centers might observe
lower mortality in those deemed to have Contraindica-
tions or they might observe a larger Neither group with
better survival.
Another limitation is that the Canadian population has
universal health care. US centers with greater diversity
and variations in medical insurance coverage may yield
different results. The advantage of this study is that the
necessary detail to make decisions of this sort may not
be possible by examining medical administrative data-
bases. In a large US registry analysis eligibility was retro-
spectively inferred by examining Medicare claims [14].
Of 128,850 older patients (at least 65 years of age) in this
analysis, 11,756 (9.1%) and 43,291 (33.6%) were classified
respectively as excellent and good potential candidates.
Using their reported percentages, about 5.1% were wait-
listed or referred for a live donor transplant. Given dif-
ferences in methodology and greater scrutiny of the
patient’s actual medical records, it is not surprising that
our study shows somewhat fewer (26.5%) age 65 years
and older patients who were deemed without contraindi-
cations (excellent and good potential candidates). How-
ever, 13.3% were referred and 8.1% (slightly more) were
actually listed. Studies from the United Kingdom and
France have also shown that patients age 65 years and
older are 93% less likely to be wait-listed compared to
younger cohorts [7,15]. In comparison we find that after
adjustments for gender and comorbidity, older dialysis
patients were 96% (95%, CI 92 to 98%) less likely to be
wait-listed compared to those age 50 years and younger.
What our study adds is that this subset of not referred
without contraindications has a very small window of
opportunity (50% are no longer eligible within 1.5 years).
The transplant evaluation may well be costly and unpro-
ductive for patients in this cohort, especially if there are
significant delays in work up. Preemptive live and pre-
emptive listing for expanded criteria deceased donor
organs would be necessary if transplantation is to occur.
However, the benefits of this approach have not been
closely studied. In our study, two patients (age 70 years
and older) received preemptive deceased donor trans-
plants and two patients (age 65 years and older) received
preemptive live donor transplants.
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Individual centers should scrutinize their referral and
listing practice to ensure eligible patients are not missed
for kidney transplantation. Patients should be tracked to
confirm that ineligible patients have poor outcomes
while conversely those who are eligible should survive a
reasonable wait time. There exists a population of inci-
dent patients that are not referred, who have no obvious
contraindications, based on Canadian eligibility criteria
and many of these may not survive long enough to re-
ceive a transplant before death or contraindication. Bet-
ter methods of assessment are needed. In addition, the
evaluation process should ideally start before dialysis,
and greater vigilance is required to consider those who
have reversible contraindications or who are lost in the
evaluation process.
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